Preclinical and clinical data for more informed and faster drug development decisions

Successful drug development requires anticipating safety and regulatory issues as early as possible. To preclude drug approval challenges, preclinical safety assessment and clinical development teams require tools that enable data-driven drug discovery and development.

How PharmaPendium helps
PharmaPendium provides comparative regulatory document-based evidence in a single translational database for better-informed risk-benefit analyses and drug candidate assessments. Users can leverage comparative information (drugs, drug classes, targets) to anticipate the best drug development strategy.

Drug Discovery & Development - Reaxys | Elsevier

PharmaPendium provides:

  • Searchable FDA and EMA regulatory documents
  • Searchable FDA Advisory Committee meeting reports
  • Dedicated search functions for the FDA Adverse Event Reporting System (FAERS), including tools to reveal differences in adverse event reporting
  • Extracted comparative data on pharmacokinetics, efficacy, safety and metabolizing enzymes and transporters

PharmaPendium helps users:

  • Identify and assess potential drug–drug interactions to define risk mitigation strategies
  • Improve the speed and success of regulatory submissions
  • Validate the best animal model to use and predict how results translate to the clinic
  • Make better-informed decisions on which drugs have the best potential to succeed in clinical development
  • Avert potential safety and efficacy risks in clinical studies

Ready to take the next step?
Contact us

The new approach to risk–benefit analyses

The new approach to risk–benefit analyses

Proper prioritization of drug candidates requires accurate risk–benefit analyses. The right information means safer, more clinical focused trials and safer marketed drugs. PharmaPendium’s new DMPK Solution provides PK and ME&T data, FDA and EMA documents, and DDI risk calculation support to facilitate these critical assessments.

Reaxys Customer Story | Elsevier

Featured customer story

Chris Penland, Senior Expert Modeller at Novartis, uses PharmaPendium to search for health authority review materials, labelling packages, adverse events and pharmacokinetic data.

Read the case study (PDF, 0.567 MB)

Read all PharmaPendium customer stories

How PharmaPendium works

PharmaPendium provides Drug Safety and FAERs data, along with dedicated data modules that provide insights and information on the critical focused areas of drug development, drug safety, ADME and drug-drug interactions.

Download the PharmaPendium fact sheet (PDF, 0.604 MB)

Efficacy Module

Optimize drug candidate selection and mitigate the risk of sub-optimal clinical trial study designs with deeply enriched, comparative efficacy data extracted from FDA and EMA drug approval documents.

Download the efficacy fact sheet (PDF, 2.3 MB)

Pharmacokinetics Module

Drive successful regulatory approval strategies by analyzing drug candidates' pharmacokinetic properties within the context of the complete landscape of approved drugs.

Download the Pharmacokinetics Module Fact Sheet (PDF, 0.464 MB)

Metabolizing Enzyme and
Transporter Proteins Module

Uncover potential drug-drug interactions with access to a unique source of searchable preclinical and clinical metabolizing enzymes and transporter data.

Download the metabolizing enzymes & transporters fact sheet (PDF, 0.661 MB)

PharmaPendium efficacy module for translational and clinical research

Mitigate the Risk of Efficacy-Related Clinical Failure - PharmaPendium | Elsevier

As clinical trials become more complex and costly, optimized study designs that take drug candidate efficacy and efficacy precedents into account are an essential part of risk mitigation. Learn how the PharmaPendium Efficacy Module can help you mitigate the risk of efficacy-related clinical failure.

Read more about PharmaPendium's Efficacy Module

Ideas and insights for industry professionals

Antibody-drug conjugates

Antibody-drug conjugates - R&D Solutions | Elsevier

Antibody-drug conjugates, or ADCs, are a class of exciting new therapeutics that utilize the patient’s own immune system, with the antibody delivering the drug right to the disease site.

Read the white paper

Cancer immunotherapy in focus

Read the story: Cancer immunotherapy in focus

Leaders in immuno-oncology met to discuss the challenges, techniques and potential of this treatment approach. View the exclusive recording of this fascinating online forum.

Watch the forum

Learn more about Elsevier's R&D Solutions for Drug Discovery & Development

Realize the potential of data-driven drug discovery and development with solutions that help you increase research efficiency and ensure a thriving R&D pipeline.
Learn more about Drug Discovery & Development solutions